Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01721044 · ClinicalTrials.gov registry record · Phase 3
A Moderate to Severe Rheumatoid Arthritis Study
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 527
- Enrollment target
NCT01721044 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 527 participants.
The verdict
NCT01721044, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 527 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had an inadequate response to a tumor necrosis factor (TNF) inhibitor, despite ongoing treatment with conventional disease-modifying antirheumatic drugs (cDMARDs).
Interventions
- DRUG Placebo
- DRUG Baricitinib
- DRUG cDMARD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 527 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01721044
The ClinicalTrials.gov registry entry for NCT01721044 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 527 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01721044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01721044 about?
NCT01721044 is a clinical study titled "A Moderate to Severe Rheumatoid Arthritis Study". The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had an inadequate response to a tumor necrosis factor (TNF) inhibitor, despite ongoi...
What is the current status of trial NCT01721044?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 527 participants. The study started on 2013-01. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01721044?
The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG), cDMARD (DRUG).
Who is sponsoring clinical trial NCT01721044?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.